The first patient has been dosed in Progenics Pharmaceuticals' (PGNX -6.2%) Phase 2/3 study, OSPREY, evaluating the diagnostic accuracy of imaging agent 18F-DCFPyL (PyL) in patients with high-risk prostate cancer undergoing PET/CT scans. The primary endpoint of the 300-subject trial is the sensitivity and specificity of PyL compared to histopathology (tissue samples examined by a pathologist).
PyL, discovered and developed at Johns Hopkins University School of Medicine, has shown high levels of uptake in sites of putative metastatic disease and primary tumors while rapidly clearing from other organs.
According to ClinicalTrials.gov, the estimated study completion date is July 2018.
Subscribe for full text news in your inbox